Clinical data | |
---|---|
Trade names | Fluorodopa F18 |
Other names | 6-fluoro-L-DOPA, FDOPA |
License data |
|
Routes of administration | Intravenous |
ATC code | |
Legal status | |
Legal status |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEBI | |
ChEMBL | |
CompTox Dashboard ( EPA) | |
Chemical and physical data | |
Formula | C9H10FNO4 |
Molar mass | 214.18 g·mol−1 |
3D model ( JSmol) | |
| |
|
Fluorodopa, also known as FDOPA, is a fluorinated form of L-DOPA primarily synthesized as its fluorine-18 isotopologue for use as a radiotracer in positron emission tomography (PET). [1]
The most common side effects are injection site pain. [2]
Fluorodopa is indicated for use in positron emission tomography (PET) to visualize dopaminergic nerve terminals in the striatum for the evaluation of adults with suspected Parkinsonian syndromes (PS). [2]
In October 2019, Fluorodopa was approved in the United States for the visual detection of certain nerve cells in adult patients with suspected Parkinsonian Syndromes (PS). [3] [4]
The U.S. Food and Drug Administration (FDA) approved Fluorodopa F 18 based on evidence from one clinical trial of 56 patients with suspected PS. [3] The trial was conducted at one clinical site in the United States. [3]